Published in Eur J Haematol on March 28, 2007
Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica (2012) 1.35
Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica (2010) 1.31
The treatment of secondary hemochromatosis. Dtsch Arztebl Int (2009) 1.24
Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes. Int J Hematol (2008) 0.96
Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome. Adv Hematol (2010) 0.94
Iron chelation therapy in myelodysplastic syndromes. Adv Hematol (2010) 0.87
Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with β-thalassemia major. Haematologica (2012) 0.82
Mayor erythropoietic response after deferasirox treatment in a transfusion-dependent anemic patient with primary myelofibrosis. Case Rep Hematol (2013) 0.79
A case of transfusion independence in a patient with myelodysplastic syndrome using deferasirox, sustained for two years after stopping therapy. Curr Oncol (2015) 0.77
Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy. Case Rep Hematol (2015) 0.76
Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis. Mediterr J Hematol Infect Dis (2014) 0.75
Treatment of Myelofibrosis: Old and New Strategies. Clin Med Insights Blood Disord (2017) 0.75
European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica (2005) 4.34
Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood (1996) 3.13
Polycythemia vera: myths, mechanisms, and management. Blood (2002) 3.01
The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol (1996) 1.60
Regulation of transferrin receptors in human hematopoietic cell lines. J Biol Chem (1984) 1.06
Improvement of erythropoiesis during treatment with deferiprone in a patient with myelofibrosis and transfusional hemosiderosis. Am J Hematol (1996) 1.01
Uptake and intracellular distribution of iron from transferrin and chelators in erythroid cells. Biol Met (1990) 0.95
Iron chelators may enhance erythropoiesis by increasing iron delivery to haematopoietic tissue and erythropoietin response in iron-loading anaemia. Acta Haematol (1993) 0.91
A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood (2005) 6.07
Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med (2012) 5.87
Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet (2003) 3.07
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica (2006) 2.54
Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica (2006) 2.14
Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol (2007) 2.14
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Haematologica (2008) 2.12
Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. Haematologica (2003) 1.94
A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol (2007) 1.77
Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol (2010) 1.77
Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood (2013) 1.68
Feasibility and efficacy of transjugular intrahepatic portosystemic shunt (TIPS) in children. J Pediatr Gastroenterol Nutr (2012) 1.55
New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood (2004) 1.51
Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol (2003) 1.46
Reproducibility of liver iron concentration measured on a biopsy sample: a validation study in vivo. Am J Hematol (2014) 1.44
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood (2010) 1.34
Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. Haematologica (2010) 1.31
Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica (2009) 1.28
Analysis of liver repair mechanisms in Alagille syndrome and biliary atresia reveals a role for notch signaling. Am J Pathol (2007) 1.26
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res (2009) 1.21
Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem (2003) 1.21
Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica (2008) 1.19
Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood (2014) 1.19
Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res (2003) 1.19
Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial. Haematologica (2008) 1.18
Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. Blood (2010) 1.17
Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. Haematologica (2009) 1.15
High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program. Haematologica (2013) 1.12
Retrospective study of 111 cases of congenital diaphragmatic hernia treated with early high-frequency oscillatory ventilation and presurgical stabilization. J Pediatr Surg (2007) 1.11
Hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: long-term results of a retrospective study on behalf of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Haematologica (2009) 1.10
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. Blood (2004) 1.09
Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. Ann Intern Med (2002) 1.06
The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica (2009) 1.05
CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease. Haematologica (2011) 1.05
Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy. Haematologica (2008) 1.04
New strategies in the treatment of the thalassemias. Annu Rev Med (2005) 1.03
Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica (2007) 0.99
Split-liver transplantation eliminates the need for living-donor liver transplantation in children with end-stage cholestatic liver disease. Transplantation (2003) 0.99
Allogeneic stem cell transplantation for thalassemia major. Haematologica (2008) 0.95
Risk of malignant lymphoma following viral hepatitis infection. Int J Hematol (2008) 0.94
Anemia in beta-thalassemia patients targets hepatic hepcidin transcript levels independently of iron metabolism genes controlling hepcidin expression. Haematologica (2008) 0.93
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. Blood (2003) 0.91
Effect of food, type of food, and time of food intake on deferasirox bioavailability: recommendations for an optimal deferasirox administration regimen. J Clin Pharmacol (2008) 0.88
HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target. Clin Cancer Res (2013) 0.87
Glucose-6-phosphate dehydrogenase polymorphism and lymphoma risk. Tumori (2007) 0.85
High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial. Haematologica (2005) 0.85
Prenatal diagnosis of proximal partial trisomy 1q confirmed by comparative genomic hybridization array: molecular cytogenetic analysis, fetal pathology and review of the literature. Birth Defects Res A Clin Mol Teratol (2014) 0.85
Interleukin-1B (IL1B) and interleukin-6 (IL6) gene polymorphisms are associated with risk of chronic lymphocytic leukaemia. Hematol Oncol (2008) 0.84
Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. Br J Haematol (2014) 0.84
Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients. J Pathol (2012) 0.84
Epidermal growth factor stimulates translocation of the class II phosphoinositide 3-kinase PI3K-C2beta to the nucleus. Biochem J (2009) 0.83
Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia. Haematologica (2013) 0.82
The role of oxidant injury in the pathophysiology of human thalassemias. Redox Rep (2003) 0.82
Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. Am J Hematol (2013) 0.81
Primary non-Hodgkin's lymphoma of the breast: a report of 11 cases. Haematologica (2004) 0.81
Clinical management of gastrointestinal disturbances in patients with myelodysplastic syndromes receiving iron chelation treatment with deferasirox. Leuk Res (2011) 0.80
Successful bleeding control by a combined conventional surgical approach and video-assisted surgery: a case report. Ann Thorac Cardiovasc Surg (2009) 0.80
Unexpected CNS localization in M2 acute myeloid leukemia: a link with past heroin addiction? Am J Hematol (2008) 0.80
A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. Cancer (2002) 0.80
Treatment of hepatitis C in patients with thalassemia. Haematologica (2008) 0.80
Household contact with pets and birds and risk of lymphoma. Cancer Causes Control (2010) 0.80
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study. Haematologica (2007) 0.79
Balloon dilatation of postoperative small bowel anastomotic stricture in an infant with apple peel intestinal atresia after serial transverse enteroplasty and jejunoileal anastomosis. J Pediatr Surg (2010) 0.78
The evolving clinical scenario of myelodysplastic syndrome: the need for a complete and up to date upfront diagnostic assessment. Eur J Intern Med (2010) 0.78
Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation. Cancer (2004) 0.78
Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients. Am J Hematol (2012) 0.78
Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients. Am J Hematol (2008) 0.77
In utero transplantation of human cord blood cells into rabbits. Transplantation (2005) 0.77
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide-dexamethasone incorporated into double autologous transplantation. Ann Hematol (2013) 0.76
Reduced Left Ventricular Contractile Reserve Identified by Low Dose Dobutamine Echocardiography as an Early Marker of Cardiac Involvement in Asymptomatic Patients with Thalassemia Major. Echocardiography (1996) 0.76
Another Step Forward in Iron Chelation Therapy. Acta Haematol (2015) 0.76
Increased leucocyte apoptosis in transfused β-thalassaemia patients. Br J Haematol (2012) 0.75
Patterns of iron distribution in liver cells in beta-thalassemia studied by X-ray microanalysis. Haematologica (2002) 0.75
Chronic cough and eosinophilic esophagitis: an uncommon association. Case Rep Gastroenterol (2011) 0.75
High prevalence of non-HFE gene-associated haemochromatosis in patients from southern Italy. Clin Chem Lab Med (2004) 0.75
Focal Foveolar Hyperplasia: A Rare Cause of Upper Gastrointestinal Bleeding in Infancy. J Pediatr Gastroenterol Nutr (2016) 0.75
Inspiratory stridor in a 12-month-old girl. Pediatr Int (2007) 0.75
Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre study. Ann Hematol (2011) 0.75
Congenital cystic lung disease: prenatal ultrasound and postnatal multidetector computer tomography evaluation. Correlation with surgical and pathological data. Radiol Med (2014) 0.75
Cardiogenic Shock during First Infusion of Anthracycline Chemotherapy in a Patient with Hodgkin Lymphoma: An Unusual Event. Cardiology (2017) 0.75
Lower gastrointestinal bleeding in a newborn caused by isolated intestinal vascular malformation. Pediatr Radiol (2002) 0.75
Iron overload, cardiac iron loading and function in myelodysplastic syndrome. Leuk Res (2009) 0.75
Specific autologous cytotoxic T lymphocytes for chronic varicella in a liver transplanted child. Pediatr Transplant (2006) 0.75
Infantile dermatofibrosarcoma protuberans: An underrecognized diagnosis? Indian J Dermatol Venereol Leprol (2015) 0.75
Sudden cardiac failure in a beta-thalassemia major patient receiving chemotherapy for acute promyelocytic leukemia. Leuk Lymphoma (2007) 0.75
Dysplasia of all granulocyte lineages in myelodysplastic evolution of essential thrombocythemia. Am J Hematol (2013) 0.75
Observation of Auer rods in crushed cells helps in the diagnosis of acute promyelocytic leukemia. Am J Hematol (2012) 0.75
Do matrix metalloproteinase-1 and glucose-6-phosphate dehydrogenase gene polymorphisms interact in promoting lymphoma development? Leuk Lymphoma (2013) 0.75
Conditioning of neonatal pigs using low-dose chemotherapy and murine fetal tissue before murine hybridoma transplantation. Transplantation (2005) 0.75
Unique method to manage ingested magnets. J Pediatr Gastroenterol Nutr (2013) 0.75
Use of cine phase-contrast MRI in the assessment of distal splenorenal shunt function. Magn Reson Imaging (2012) 0.75
Marginal zone B-cell lymphoma arising in donor cells in a Hepatitis-C virus infected patient over 20 years after allogeneic bone marrow transplantation. Leuk Lymphoma (2008) 0.75